Drug Database
AD

AD-104 (AD104 / AD 104)

✓ Approved

Addpharma · 小分子 · 小分子

什么是 AD-104?

AD-104 是一种小分子,由Addpharma研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名AD104, AD 104
公司Addpharma
药物类别小分子
给药途径Oral (PO)
状态Approved

治疗适应症

AD-104 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Metabolism and nutrition disordersHyperlipidaemia✓ Approved

相关研究文献

PubMedTherapeutic advances in neurological disorders2026-11-18

Alzheimer's disease and olfactory dysfunction: the role of TNF-α and mechanisms involving ferritin and P-tau199 from an exploratory cross-sectional study.

Wang Ruidan R, Lian Tenghong T, Li Jing J, Guo Peng P et al.

Olfactory dysfunction (OD) is a common and important symptom at the early stage of Alzheimer's disease (AD). Growing evidence has showed that abnormal iron metabolism played important roles on the development and progression of AD. However, the specific roles and potential mechanisms of abnormal iron metabolism in AD with OD (AD-OD) patients are still unclear. To explore the iron metabolism changes in brain and the potential neuroinflammatory and neuropathological mechanisms of OD in AD patients. A cross-sectional study of AD-OD and AD with no OD (AD-nOD) patients with measurements of cerebrospinal fluid (CSF) biomarkers, including iron metabolism-related proteins, neuroinflammatory factors and AD biomarkers. AD patients were divided into AD-OD and AD-nOD groups according to the overall olfactory function assessed by Sniffin' Sticks test. The levels of iron metabolism-related proteins, neuroinflammatory factors and AD biomarkers in CSF were measured. CSF levels of ferritin, tumor necrosis factor-α (TNF-α) and phosphorylated tau 199 (P-tau199) in AD-OD group were significantly higher than those in AD-nOD group. Overall olfactory function was significantly and negatively correlated with CSF levels of ferritin, TNF-α and P-tau199 in AD patients. CSF levels of ferritin, TNF-α and P-tau199 were significantly and positively correlated with each other in AD-OD group. TNF-α mediated 29.6% of the effect of ferritin on P-tau199 in CSF. AD-OD is correlated with the elevated CSF levels of ferritin, TNF-α and P-tau199. CSF Ferritin, TNF-α and P-tau199 levels are associated with each other and collectively correlated with OD in AD patients. TNF-α partially mediates the effect of ferritin on P-tau199 in CSF.

PMID 43048402
阅读全文 →
PubMedAlzheimer's & dementia (New York, N. Y.)2026-11-18

Atomoxetine and risk of Alzheimer's disease in older adults.

Bress Adam P AP, Xu Yizhe Y, Marcum Zachary A ZA, Davis Matthew M et al.

Experimental studies and a previous small, randomized trial suggest that atomoxetine, a selective norepinephrine reuptake inhibitor, may be efficacious in the prevention or disease modification of Alzheimer's disease (AD). Its association with incident AD is unclear. This non-concurrent prospective study emulated a target trial among Medicare beneficiaries (January 1, 2007-December 31, 2023). The primary outcome was AD, determined using a validated algorithm. We estimated 5- and 10-year risk ratios (RRs) and risk differences (RDs). Analyses were examined overall and by indication. This study included 70,367 person-trials (74.6% ≥70 years; 59.5% female; 86.7% non-Hispanic White). Initiation of atomoxetine versus no initiation was not associated with 5- or 10-year risk of AD but was associated with lower risk of AD-free death. In indication-specific analyses, atomoxetine was associated with lower 5-year risk of AD and AD-free death among individuals with depression. Initiation of atomoxetine was not associated with lower risk of AD later in life. The lower risk of AD among people with depression warrants further study.

PMID 43048136
阅读全文 →
PubMedJournal of Alzheimer's disease : JAD2026-11-18

Network proximity-based drug repurposing identifies anti-inflammatory therapies for Alzheimer's disease.

Cammann Davis D, Cummings Jeffrey L JL, Zhou Yadi Y, Cheng Feixiong F et al.

BackgroundNeuroinflammation is implicated as a driver of cellular dysfunction in Alzheimer's disease (AD), yet there are currently no FDA-approved drugs to treat this pathology. Network models of protein-protein interactions (PPI) show promise in identifying drug mechanisms of action targeted towards disease pathologies.ObjectiveWe sought to identify repurposable drugs to treat neuroinflammation by screening drug targets on an extensive PPI network against proteins involved in AD neuroinflammatory pathways.MethodsWe identified 133 immune system pathway genes from AD genomic and transcriptomic studies, creating a network module on a human PPI network. We assessed the network proximity of this module to drug target modules across three screenings: inflammation-targeted drugs with a negative AD clinical trial, repurposed compounds in AD clinical trials as of 2025, and 1700 FDA-approved compounds. Drugs were prioritized if they had Z-scored proximity less than -2.0, a false-discovery rate corrected p-value less than 0.05, and evidence in transgenic mouse models or AD clinical trials.ResultsWe found that anti-inflammatory drugs with negative AD clinical trials had low proximity to AD-neuroinflammatory targets, while the phase 2 drug baricitinib was significantly proximal. Screening 1700 FDA-approved compounds, we found 15 with significant network proximity to AD-immune system targets. Notably, cabozantinib, plerixafor, and bevacizumab had positive biomarker effects in AD mouse models.ConclusionsWe provide an in-silico line of evidence for several repurposable drugs to be tested further in-vitro and in-vivo studies of AD.

PMID 43048891
阅读全文 →
PubMedCellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology2026-11-18

Andrographolide Induces Apoptosis in Burkitt's Lymphoma by Suppressing Antioxidant Defense Rather Than Ferroptosis.

Liu Haiyun H, Ke Bo B, Wang Tiantian T, Liu Tingting T et al.

This study aimed to investigate whether andrographolide (AD) exerts cytotoxic effects on Burkitt's lymphoma cells by inducing ferroptosis. Burkitt's lymphoma cell lines CA46 and Raji were cultured in vitro. AD-induced cytotoxicity was assessed using the CCK-8 assay and AO/PI staining. Ferroptosis involvement was evaluated through ferroptosis inhibitor rescue assays and ferroptosis-related biochemical analyses. Western blotting was performed to measure the expression of apoptosis-related proteins (cleaved caspase-3, Bcl-2, Bax), ferroptosis-related proteins (GPX4, xCT, ACSL4), and the phosphorylation levels of Nrf2. Additionally, reactive oxygen species (ROS) generation following AD treatment was analyzed by DCFH-DA staining. Mitochondrial membrane potential was measured using JC-1 fluorescence staining. AD treatment significantly reduced the viability of CA46 and Raji cells, and this cytotoxicity was not rescued by the ferroptosis inhibitor Ferrostatin-1. AO/PI staining revealed a marked increase in PI-positive cells upon AD treatment. Biochemical assays showed no significant changes in malondialdehyde (MDA) levels or ferrous iron (Fe²⁺) content after AD exposure. Western blot analyses indicated no significant alteration in xCT expression, while ACSL4 protein levels were downregulated and GPX4 levels were upregulated following AD treatment. Moreover, Nrf2 phosphorylation was significantly decreased, concurrent with increased expression of apoptosis markers cleaved caspase-3 and Bax and decreased Bcl-2 expression. Mitochondrial membrane depolarization was observed in AD-treated cells. DCFH-DA fluorescence imaging demonstrated a substantial increase in intracellular ROS in AD-treated cells. The ROS scavenger NAC markedly attenuated AD-induced cell death as shown by AO/PI staining and reduced the upregulation of cleaved caspase-3 (P < 0.05); NAC also partially restored Nrf2 phosphorylation (P < 0.05). AD inhibits Burkitt's lymphoma cell viability primarily by inducing apoptosis rather than ferroptosis.

PMID 43046760
阅读全文 →
PubMedAlzheimer's research & therapy2026-11-18

Increases in a pivotal bioactive peptide in specific brain regions reflect the progression of pathology in Alzheimer's disease.

Komorowska Joanna J, Ranglani Sanskar S, McCann Heather H, Shepherd Claire E CE et al.

Abnormal activation of a developmental process driven by a bioactive peptide T14, is posited as a key mechanism in the degeneration of the primarily vulnerable nuclei during the prodromal phase of Alzheimer's Disease (AD). We use a range of anatomical, biochemical and genetic approaches to explore changes in T14 and its target, α7nAChR, in AD and in individuals with mood disorders, a frequent prelude to the disease. Using paired samples from the same patients, levels of T14 and α7nAChR increased in the hippocampus across the AD continuum. In contrast, in early Braak stages, T14 levels in the midbrain reach a plateau and are primarily localised to glia. Moreover, in a cognitively healthy cohort, CSF derived ex vivo revealed a differential profile between T14 and tau levels in individuals with mood disorders, a well-known precursor to AD. These observations confirm a key role of T14 in the neuropathology of AD. Finally, we show a Braak-stage dependant and selective increase in an acetylcholinesterase isoform (AChE-R) already associated with AD pathology, where the profile corresponds closely to that of T14, thereby providing further clues regarding its provenance. By highlighting region and cell-specific changes in the T14 profile as AD progresses, this study further validates a key role for T14 in the progression of neurodegeneration. Finally, the mood disorder-dependent changes based on T14 in CSF might reflect dysfunction in the primarily vulnerable isodendritic core and as such be viewed as a possible, albeit non-exclusive, prelude to AD. Collectively, these results underscore the importance of T14 in AD aetiology and could aid the development of precise and effective therapeutics to target its progression.

PMID 43046249
阅读全文 →
PubMedFood science & nutrition2026-11-18

Ganoderic Acid A Ameliorates Recognition Memory Deficits and Anxiety- and Depression-Like Behaviors in APP/PS1 Mice: Association With Histone Lactylation and Ferroptosis.

Fang Ziyi Z, Yue Jiamin J, Lu Qingyang Q, Shao Nan N et al.

Alzheimer's disease (AD) is a degenerative disorder of the central nervous system, characterized by core symptoms of memory and cognitive dysfunction. However, neuropsychiatric abnormalities such as anxiety and depression are commonly observed during the progression of AD. Aberrant histone lactylation is a key epigenetic mechanism that promotes AD progression. Ganoderic acid A (GAA), one of the major bioactive components in Ganoderma lucidum, has been shown to ameliorate AD; however, whether GAA ameliorates anxiety- and depression-like behaviors in AD, and whether it exerts neuroprotective effects through regulation of the histone lactylation-ferroptosis axis, remain unexplored. In this study, using APP/PS1 mice as a model, recognition memory as well as anxiety- and depression-like behaviors were evaluated. Furthermore, an AD cell model was established by treating HT22 cells with Aβ25-35 to investigate the mechanism of GAA in vitro. The results showed that GAA improved recognition memory, anxiety-, and depression-like behaviors in APP/PS1 mice and suppressed histone lactylation in the hippocampus. In AD cells, GAA treatment was accompanied by decreased LDH levels, reduced lactate contents, p300 downregulation, HDAC1 upregulation and reduced histone lactylation. Ferroptosis-related assays showed that GAA treatment downregulated TFR1, upregulated FTH1, decreased Fe2+ levels, downregulated ACSL4, upregulated NRF2, SLC7A11, and GPX4, and decreased ROS and MDA levels, while increasing SOD and GSH levels and total antioxidant capacity. Collectively, these findings indicate that GAA effectively ameliorates recognition memory deficits and anxiety- and depression-like behaviors in APP/PS1 mice, possibly via the histone lactylation-ferroptosis axis, thereby exerting anti-AD effects. Our study suggests that GAA could be exploited as a novel functional food ingredient for the treatment or prevention of AD.

PMID 43047614
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多AD-104